RMD

ResMed Inc. 10-Q Filing Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep disordered breathing. The report covers the quarterly period ended March 31, 2001, and the nine-month period ended March 31, 2001. The Company's principal manufacturing operations are located in Australia, with distribution sites in the U.S., U.K., Singapore, and Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 42% ($12.7 million) for the quarter and 29% ($24.0 million) for the nine months compared to the prior year periods. Growth was driven by increased unit sales of flow generators and the acquisition of MAP Medizin-Technologie GmbH ("MAP") on February 16, 2001.
• Profitability Impact: Despite revenue growth, the Company reported a net loss of $10.2 million for the quarter, compared to a net income of $5.8 million in the prior year quarter. This was primarily due to a $17.7 million non-cash write-off of purchased in-process research and development (IPR&D) associated with the MAP acquisition and a $0.55 million restructuring charge.
• Balance Sheet Shifts: Total assets increased from $115.6 million to $201.0 million, largely due to the acquisition. Goodwill increased from $5.6 million to $49.6 million. Current liabilities rose significantly to $109.7 million, driven by the $35.4 million short-term debt and $40.1 million payable to former MAP shareholders.
• Foreign Currency: The Company recorded a net loss of $11.8 million from foreign currency translation adjustments for the quarter, compared to $5.7 million in the prior year.

Outlook, Risks, and Management Commentary

• Acquisition Integration: The MAP acquisition contributed $2.9 million in revenue for the quarter. Management expects to fund the remaining acquisition balance ($40.1 million) via a bridging loan and is negotiating term and revolving loan facilities with Deutsche Bank AG and Union Bank of California.
• Capital Expenditures: Capital expenditures were $24.4 million for the nine months, significantly higher than the prior year, primarily due to the purchase of land and buildings for the U.S. headquarters in Poway, California.
• Legal Contingencies: The Company is engaged in patent litigation against Respironics (U.S. and Australia) and Hofrichter GmbH (Germany). While settlements were reached in some matters (MPV Truma, Respironics Australia), the Respironics U.S. litigation remains pending with summary judgment motions granted against ResMed, which intends to appeal.
• Liquidity: Management expects to satisfy short-term liquidity requirements through cash on hand, operating cash flow, and existing revolving loan facilities. A 90-day bridging loan of AUD 80.0 million was obtained to facilitate the MAP settlement.

Investor Verification Checklist

• Debt Financing Status: Verify the final terms of the term and revolving loan facilities being negotiated to replace the $35.4 million short-term debt and fund the $40.1 million MAP payable due May 16, 2001.
• IPR&D Write-off: Assess the long-term viability of the MAP technology written off ($17.7 million) and the assumptions used in the valuation (discount rates of 27-33%).
• Legal Outcomes: Monitor the appeal process regarding the Respironics patent litigation in the U.S. District Court for the Western District of Pennsylvania.
• Foreign Exchange Exposure: Review the effectiveness of the foreign currency hedging program given the significant translation losses ($11.8 million for the quarter) and the Company's exposure to the Australian dollar and Euro.
• Pro-Forma Performance: Compare reported results against the pro-forma net income of $20.3 million for the nine months ended March 31, 2001, which excludes the non-recurring acquisition charges.